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Abstract. We have previously shown that peptides de- 
rived from the thrombospondin sequence, CSVTCG, 
promoted tumor cell adhesion.  To further investigate 
this observation, the CSVTCG-tumor cell adhesion 
receptor from A549 human lung adenocarcinoma cells 
was isolated and characterized.  A  single protein peak 
was isolated by CSVTCG affinity chromatography 
which also analyzed as a  single peak by anion ex- 
change chromatography.  The purified protein had a pI 
of 4.7 and analyzed on SDS-gels as a  single band of 
Mr  =  50,000 under nonreducing conditions and as two 
protein bands of Mr  =  50,000, and 60,000 under 
reducing conditions.  Purified CSVTCG binding protein 
(CBP) bound either CSVTCG- or TSP-Sepharose but 
showed little interaction with either VCTGSC- or 
BSA-Sepharose.  CBP was cell surface exposed. 
CSVTCG derivatized with [1251] Bolton-Hunter reagent 
was taken up by cells in a dose-dependent manner 
and the cell association was inhibited with a 
monospecific polyclonal anfi-CBP antibody. Examina- 
tion of the cell proteins crosslinked to labeled 
CSVTCG by SDS-gel electrophoresis revealed one 
band that comigrated with purified CPB. Using an in 
vitro binding assay,  purified CBP bound mannose, 
galactose, and glucosamine-specific lectins.  CBP 
bound TSP saturably and reversibly. The binding was 
Ca+2/Mg  +2 ion dependent and inhibited with fluid 
phase TSP and anti-CBP.  Little or no binding was ob- 
served on BSA, fibronectin, GRGES, and GRGDS. 
Heparin, but not lactose, inhibited binding.  Anti-CBP 
IgG and anti-CSVTCG peptide IgG inhibited A549 
cell spreading and adhesion on TSP but not on 
fibronectin and laminin.  These results indicate that 
CBP and the CSVTCG peptide domain of TSP can 
mediate TSP-promoted tumor cell adhesion. 
T 
HROMBOSPONDIN (TSP) 1  is  a  large  multi-domain 
protein that was originally purified from platelets (15) 
but has  since been found  in many  tissues including 
bone (23), muscle (39), skin (38, 39), and brain (20). A ma- 
jor physiological  function of this protein appears to involve 
cell-extracellular  matrix interaction  because purified prepa- 
rations of TSP promote cell-substratum interaction of a vari- 
ety of cell types (34),  including  platelets  (30, 33). Support 
for a role of TSP in matrix-cell  interaction  was demonstrated 
in a recent study by Arbeille et al. (3) who showed that TSP 
was localized in microfibrils  at the junction between base- 
ment membrane and connective tissue in sections of human 
placenta,  porcine  arteries  and  skin.  Additional  support 
comes from several in vitro studies which show that TSP has 
a high binding affinity for components of the basement mem- 
brane such as collagen  (8), fibronectin  (13), and heparan- 
sulfate containing  macromolecules (9). 
Recently, our group (32) and two others (21, 22) indepen- 
dently demonstrated that peptides containing  the sequence 
VTCG promoted cell attachment.  Rich et al.  (22) showed 
1. Abbreviations used in this paper: BCA, bicinchoninic acid; CBP, CSVTCG 
binding protein; TSE thrombospondin. 
that several peptides containing  VTCG from region H of the 
circumsporozoite protein isolated from the malarial parasite 
Plasmodium vivax strongly  promoted the attachment of T 
cells and myeloid cells.  Prater et al. (21) showed that pep- 
tides containing VTCG and having sequences corresponding 
to  amino  acid  residues  424-442  and  481-499  of  TSP 
promoted  G361  melanoma  cell  attachment.  We  demon- 
strated  that  peptides  having  the  sequence CSVTCG  and 
highly  homologous analogues promoted the attachment of 
B16-F10 mouse melanoma, A549 human lung adenocarci- 
noma,  bovine aortic  endothelial  cells and  rabbit  smooth 
muscle cells. These peptides also inhibited platelet aggrega- 
tion and tumor cell metastasis presumably by competing 
with cell surface TSP receptors. 
In this report we provide evidence that the anti-metastatic 
CSVTCG peptides bind tumor cell receptors that function as 
TSP tumor cell adhesion receptors. These receptors are dis- 
tinct  from known TSP receptors such as the integrins  and 
may represent a new class of high  affinity TSP receptors. 
These data also provide additional support for the hypothesis 
that TSP plays a major role in mediating tumor cell adhesive 
interactions. 
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Materials 
All  reagents,  unless  specified  otherwise,  were  purchased  from  Sigma 
Chemical Co.  (St.  Louis,  MO).  Peptides  were purchased from Multiple 
Peptide  Systems  (San Diego,  CA).  Tissue culture supplies,  Na[12Sl] and 
[t25I] Bolton-Hunter reagent were purchased from ICN Flow (Irvine, CA). 
Reagents for SDS-PAGE were obtained from Bio-Rad Laboratories (Rich- 
mond,  CA).  lodobeads and Bis(sulfosuccinimidyl)  suberate (BS  3) were 
purchased from Pierce Chemical Co.  (Rockford,  IL).  Microtiter plates, 
Removawell Immulon 4, were purchased from Fisher Scientific (Malvern, 
PA). CN-activated  Sepharose  and Phast System  reagents were purchased 
from Pharmacia LKB Biotechnology  Inc.  (Piscataway, N J). 
Cell Culture 
Human A549 lung adenocarcinoma cells were cultured in DME containing 
10% FCS, 100 units/nil  penicillin, 100 #g/rrd of streptomycin,  and 50 #g/ml 
of gentamicin sulfate.  Cells were grown to near confluancy and were har- 
vested in DME containing  0.02 % EDTA. Cells were washed twice in Hepes 
buffered  saline and the pellet either used immediately  for purification of 
CSVTCG binding protein or stored frozen at -70~  for future use. 
Cell Adhesion Assay 
Celt adhesion was performed by addition of cells suspended in DME (31) 
in an eight-well glass tissue culture slide spotted with various proteins (34). 
Anti-CSVTCG binding protein IgG (200 #g/ml) was added to the cell sus- 
pension, the cells were washed to remove excess antibody,  and incubated 
for 1 h on BSA, FN, laminin or TSP-coated tissue culture plates. The cells 
were then aspirated, wells washed twice with PBS, the cells fixed, and ad- 
herent ceils counted. To evaluate the effect of anti-CSVTCG peptide  anti- 
body, TSP-coated surfaces were treated with either I00 #g/ml oflgG or 100 
#g/rnl affinity purified anti-CSVTCG IgG in PBS for 30 rain before addition 
of cells. 
Direct ELISA 
ELISA assays were performed as previously described (36). Briefly, micro- 
titer plates were  coated with 2  #g of protein either BSA,  FN,  TSP, or 
CSVTCG binding protein and blocked with 1% BSA for 1 h. Wells were 
incubated for 1 h with 50 #1 of various dilutions of the first antibody in 10 
mM phosphate buffer, pH 7.4, containing 150 mM NaC1 and 0.05% Tween- 
20 (PBS-T). Wells were then washed three times in PBS-T and incubated 
for 1 h with 50 #1 of a 1:800 dilution in PBS-T of alkaline phosphatase cou- 
pled rabbit anti-goat IgG. Wells were washed three times with PBS-T fol- 
lowed  with three washes  of PBS-T buffer  containing no Tween-20  and 
treated with 50 #1 of alkaline phosphatase substrate solution (1 mg/ml of 
p-nitrophenylphosphate in 0.10  M  glycine,  pH  10.4,  containing 1 mM 
ZnC12 and 1 mM MgC12). After 30 min, color development was stopped 
by the addition of 5/tl of I N NaOH and absorbances determined at 405 nm. 
Antibodies 
CSVTCG was coupled to maleimide activated keyhole limpet hemocyanin 
(KLH) according to the instructions provided with the Pierce Imject Acti- 
vated Immunogen Conjugation Kit, Pierce Chemical Co.  Approximately 
4 mg of peptide was coupled to 2 mg of KLH. A goat was injected sub- 
cutaneously with 1 nag of peptide-protein conjugate suspended in complete 
Freund's and boosted with two additional  injections  of 500 #g of peptide- 
protein conjugate in incomplete Freund's adjuvant three and 5 wk after the 
first injection. Goat immunization and collection of serum was accomplished 
commercially through Hazelton Research  Products,  Inc.  (Denver,  PA). 
Polyclonal  anti-CSVTCG  was  affinity  purified  on  TSP-Sepharose. 
Briefly, IgG prepared by ammonium sulfate precipitation of 100 ml of anti- 
sera was dissolved in 50 ml of Hepes-buffered  saline,  pH 7.35  (column 
buffer), and passed over a  1 ml column of Sepharose containing 2 mg of 
coupled TSP. The TSP column was then washed with 10 ml of  column buffer 
and eluted with 0.1 M sodium citrate buffer, pH 2.7. One ml fractions were 
collected  in tubes containing 50 #1 of 1 M Tris base in order to neutralize 
the final solution. Protein fractions were pooled, concentrated and assessed 
for anti-TSP activity by ELISA analysis. 
Polyclonal CSVTCG binding protein antiserum was raised in a rabbit af- 
ter four 50 #g injections every 3-4 wk. The first injection was given with 
complete Freund's adjuvant  and subsequent injections were administered 
with incomplete Freund's adjuvant.  Rabbit immunization and collection of 
serum was accomplished  commercially through Hazelton Research  Prod- 
ucts,  Inc. Antibody titers and specificity were determined by ELISA. 
TSP Purification 
TSP was purified from Ca  +2 ionophore A23187-activated human platelets 
as previously  described (37). 
Protein Assays 
Protein concentrations were determined by the bicinchoninic acid protein 
assay, adapted for microtiter plates, as described by Pierce Chemical Co. 
(Rockford,  IL). BSA was used as standard. 
Gel Electrophoresis 
SDS-PAGE was performed using the Pharmacia Phast Gel or Biorad mini- 
slab gel systems.  Protein samples were reduced with 5% beta-mercapto- 
ethanol. Gels were silver stained, dried, and autoradiograms were prepared 
from the dried gels using intensifying  screens  (DuPont Cronex Lighting 
Plus  screens  mounted  in  Spectroline  Cassettes,  Reliance  X-Ray  Inc., 
Oretand, PA). Kodak X-Omat-AR  film (Eastman Kodak Co., Rochester, 
NY) was used and developed according to the instructions provided with 
the film. Films were exposed  for varying lengths of time at -70~ 
Protein and Cell Labeling 
Purified CSVTCG-binding protein was labeled with [125I]iodine  using Io- 
dobeads as previously described (10). Briefly, 12 #g of purified protein dis- 
solved in 100 #1 of octylglucoside  buffer was incubated with one Iodobead 
for 10 rain. Unreacted iodide was removed on a small column of Sephadex 
G-25 equilibrated in octylglucoside buffer as previously described (29). The 
specific activity of protein obtained in a typical experiment was 0.5-2.0 x 
10  4 cpm/ng. 
A549 cells were surface labeled with [1251]iodine  using lactoperoxidase 
(29).  Briefly,  celts  from  a  75-mm  flask  containing a  near  confluent 
monolayer  of cells were harvested, washed,  and suspended  in 0.5 mi of 
DME  containing 0.17 units/ml lactoperoxidase  and 500  uCi of [12sI]- 
iodide. A 1 #1 aliquot of 0.002 % H202 in PBS was added with gentle mix- 
ing every minute for 4 rain. The iodination was then stopped by the addition 
of 600 #1 of 2 mM NaI in PBS, ceUs washed twice in PBS, and the pellet 
solubilized  in NP-40 detergent  as described below for purification  of the 
CSVTCG binding protein. 
Preparation of Coupled-Sepharose Gels  for 
Specificity Experiments 
Approximately  4 mg of either CSVTCG or VCTGSC or 2 nag of TSP or 
BSA were coupled to 1 ml of CN-activated  Sepharose according to the in- 
structions provided by  Pharmacia LKB  Biotechnology,  Inc.  Gels were 
equilibrated in 20 mM Tris HC1, pH 7.0, containing 1 mM CaC12, 1 mM 
MgCI2, and 5 mM octyt glucoside before use. 
Preparation of pZq]-Bolton-Hunter 
Derivatized CSVTCG 
A 100 #1 aliquot of 10 mg/ml solution of CSVTCG in PBS was added to 
1 mCi of BoRon-Hunter reagent previously sparged with nitrogen to remove 
benzene as indicated in the instructions provided with the Bolton-Hunter 
kit. The reaction mixture was incubated with occasional  shaking for 1 h at 
4~  A  100 #1 aliquot of a  1 mg/mi glycine  solution was then added to 
quench  any  unreacted  reagent.  The  final  reaction  mixture  was  chro- 
matographer on a 2-ml column of Sephadex (310 equilibrated in PBS con- 
taining 0.1% gelatin.  The void volume peak (400 #1 containing 4.1  ￿  108 
cpm) was collected  and stored under nitrogen at 4aC until needed. 
Cell Association and Cross-linking of 
[usI]-Bolton-Hunter Derivatized CSVTCG 
A549 cells wore grown to near confluency in 6 well tissue culture plates. 
The media was then removed and cells rinsed twice with serum-free DME. 
Wells were treated with 1 ml serum-free media containing varying amounts 
of peptide (5  x  106 cprrdml  in a  typical experiment) for t  h  at 37*C. 
Monolayers  were  washed twice  with PBS,  harvested with EDTA  and 
counted to  determine cell-associated  CSVTCG.  For  cross-linking,  the 
washed monolayers  were treated with 0.5 ml of a 2 mM BS  3 solution in 
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monolayer extracted with 100 p.l of SDS gel sample buffer containing 4 M 
urea,  1 mM EDTA, 1 mM PMSF, and 100/~1 leupeptin. The extracted cell 
layer was then analyzed by SDS-gel electrophoresis followed by autoradiog- 
raphy. 
Purification of CSVTCG  Binding Proteins 
CSVTCG binding proteins were purified by affinity chromatography  from 
A549 detergent extracts. Briefly, approximately 4.0 x  107 A549 cells were 
harvested with EDTA and the pellet washed once with DME. The cell pellet 
was then homogenized on ice with 5 rnl of solubilization buffer (10 mM Tris 
HC1, pH 7.5, containing 0.5%  NP-40,  1 mM CaCI2, 1 mM MgC12, 100 
t~M leupeptin,  1 mM phenylmethyl sulphonyl fluoride). The cell lysate was 
then centrifuged at 4"C for 20 min at 100,000 g to remove undissolved mate- 
rial. The supernatant was passed three times over a 5 ml column containing 
4 nag of CSVTCG coupled to 1 ml of CN-activated Sepharose equilibrated 
in Hepes buffered saline, pH 7.35. The unbound material was washed with 
20 ml of column buffer (10 mM Tris HC1, pH 7.5, containing 0.05 % NP-40, 
1 mM CaC12, 1 mM MgC12, 100/~M leupeptin,  1 mM phenylmethyl sul- 
phonyl fluoride). Bound material was eluted with elution buffer (0.1 M Tris, 
pH 10.2, containing 0.05% NP-40, 1 mM CaC12, 1 mM MgC12, 100/~M 
leupeptin,  1 mM phenylmethylsulphonyl fluoride) by collecting 1 ml frac- 
tions in a tube containing 70/~1 of 1 N HC1 to neutralize the final solution. 
The proteins eluting in the first 10 fractions were applied to an anion ex- 
change column (Mono Q, Pharmacia LKB Biotechnology, Inc.) equilibrated 
in anion  exchange column buffer (20 mM Tris HC1, pH 8.0, containing 
5 mM octyl glucoside). The bound material was eluted at 0.7 ml/min with 
a 10 ml gradient of NaC1 (100% 1 M NaCI) and the column monitored at 
280 and 260 nM. The bound material routinely began to elute at 0.3 M NaC1 
and the gradient was held to allow the proteins to elute isocraticaily. The 
eluted fractions were concentrated  and analyzed for TSP binding activity 
and  further  characterized  by  SDS-gel  electrophoresis  and  isoelectric 
focusing. 
Binding Assay 
[12sI]-labeled CSVTCG binding protein  and unlabeled  CSVTCG binding 
protein were combined in binding buffer (20 mM Tris buffered saline, pH 
7.35, containing  1 mM CaC12, 1 mM MgC12, 0.05% NP-40) such that the 
final  concentration  was  1.8  /~g/ml and  100  t~l  of  solution  contained 
",,200,000 cpm. Microtiter wells were coated with proteins and peptides by 
drying under nitrogen a 50 tzl aliquot of a 40/zg/ml solution of protein or 
peptide in 20 mM bis-tris-propane  buffer, pH 6.5. Wells were then treated 
with 200 t~l of 1% BSA for 1 h, washed once with binding buffer, and in- 
cubated with 100 td of [12sI]-labeled CSVTCG binding protein for 60 rain. 
Well were then washed three  times by aspiration  with 200/~I of  binding 
buffer and bound  radioactivity  determined  by counting  each well in a 
gamma counter. 
Western Immunoblotting 
Anti-CSTSCG  antibody  was  characterized  by  Western  immunoblotting 
using Pharmacia's Phast electrophoresis  system. Whole cell extracts were 
prepared  by dissolving  4  ￿  105 cells  in  100/~1 of SDS  sample  buffer. 
Approximately, 100 ng of protein was separated under reducing conditions 
on an 8-25 % polyacrylamide  gradient  SDS gel.  Gels were either silver 
stained or the proteins were electrophoretically transferred onto nitrocellu- 
lose paper. The paper was then blocked with 3 % BSA in PBS-T and treated 
for 1 h with either 1.37/~g/ml of ai~nity purified goat anti-CSVTCG or 50 
/zg/ml anti-CSVTCG binding protein IgG for 1 h, washed with PBS-T, de- 
veloped  according  to the instructions  provided  with  the VECTASTAIN 
ABC immunoperoxidase system, (Vector Laboratories,  Burlingame, CA). 
Controls  were the respective control IgG fractions. 
Results 
Purification of CSVTCG Binding Protein 
Approximately,  4.0  ￿  107 A549  cells were grown to near 
confluency and harvested with EDTA. The washed pellet was 
solubilized with NP-40 detergent and the extract  applied to 
a CSVTCG-Sepharose column. One protein peak was eluted 
at high pH in the first  10 fractions as detected by SDS-gel 
Figure 1. SDS-gel analysis of the high pH eluate from the CSVTCG 
affinity column. Detergent extracts of A549 cells were adsorbed on 
CSVTCG-Sepharose,  unbound  proteins  washed,  and bound pro- 
teins eluted at high pH.  Fractions were analyzed under reducing 
conditions by SDS-gel electrophoresis on a  7.5 % polyacrylamide 
gel and visualized by silver staining. Lanes I  and 8, tool standards; 
lanes 2-7,  column fractions  1,  3,  5,  7, 9,  and  10,  respectively. 
electrophoresis under reducing  conditions (Fig.  1). This ma- 
terial  could be  adsorbed to an anion  exchange  column at 
pH 8 and eluted with 0.30 M NaCI as a single homogenous 
peak having a high ratio of absorbance at 260 to 280 nm (Fig. 
2). The purified material analyzed on SDS-gel electrophore- 
sis  as two polypeptide bands  of Mr  =  60,000  and 50,000 
under  reducing  conditions  and  one  polypeptide  of Mr  = 
50,000 under nonreducing conditions (Fig.  3).  Analysis by 
isoelectric  focusing  revealed  that  the  purified  material 
resolved as one band with a pI in the range of 5.00-4.65 (Fig. 
4). Approximately,  100 #g of protein was recovered from 4 
x  107 cells. 
Specificity of the Interaction of CSVTCG with the 
CSVTCG Binding Protein 
To determine if the CSVTCG binding protein binds  CSV- 
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Figure 2.  The anion exchange elution profile of CSVTCG binding 
protein. The high pH eluate from the CSVTCG affinity column was 
applied to a Mono Q anion exchange column and eluted with 0.3 M 
NaCI as  described  in  Materials  and  Methods.  The  column was 
monitored at 260 and 280 rim. The first arrow at the top of the chro- 
matogram indicates when the sample was applied and the second 
arrow  shows when the 0.3  M  NaC1 was applied to elute the ad- 
sorbed proteins. 
Tuszynski et al. Purification of a Thrombospondin Receptor  515 Figure 3. SDS-gel analysis of the CSVTCG-binding proteins.  De- 
tergent  extracts  of A549  cells  and  p25I]iodine surface  labeled 
A549  cells  were  adsorbed  on a  CSVTCG  column,  the  column 
washed with column buffer, and then eluted with elution buffer, pH 
10.2 or with 0.1 M citrate buffer, pH 3.0. The nonradioactive sample 
was further chromatographed on anion exchange chromatography 
as described in Materials and Methods. The non-radioactive sam- 
ple was then labeled with [~25I]iodine. Lanes 1 and 2, Coomassie 
blue stained and labeled CSVTCG binding protein; lanes 3 and 4, 
autoradiogram of  lanes I and 2; lane 5, autoradiogram of  CSVTCG 
binding  protein  isolated  from [~25I] surface  labeled  A549  cells. 
Samples in lanes I and 3 were reduced with 5 % ~ mercaptoethanol. 
Samples in lanes 2, 4, and 5 were nonreduced.  The gel was 8% 
polyacrylamide. 
TCG specifically two experiments were performed. In the 
first  experiment,  [t2sI]-labeled  CSVTCG  binding  protein 
was evaluated for its capacity to bind and be eluted from 
Sepharose derivatized with either TSP,  BSA, CSVTCG, or 
VCTGSC.  CSVTCG binding protein could only be bound 
Figure 4.  Isoelectric  focusing analysis of [~25I]CSVTCG binding 
protein,  p~sI]CSVTCG binding protein  (100,000 epm) was ana- 
lyzed on a pH 2.5-6.5 isoelectric focusing gel. The arrow indicates 
where the sample was applied on the gel and the small amount of 
material  remaining  at  the  point  of  application  represents 
nonspeeifically  adsorbed  material.  Similar  amounts  of material 
were adsorbed to the point of application when the sample was ap- 
plied at different places on the gel but the major band always fo- 
cused at pH 4.7 (data not shown). 
Figure  5.  Interaction  of  [~25I]CSVTCG binding  protein  with 
Sepharose coupled to various peptides and proteins.  100 #1 slurries 
of  coupled-Sepharose derivatized with either TSP, BSA, CSVTCG, 
or VCTGSC as described  in Materials  and Methods were equil- 
ibrated in 20 mM Tris HCI, pH 7.0, containing  1 mM CaCI2 and 
1 mM MgC12 and 5 mM octyl glucoside (equilibration buffer). To 
each resin 1 x  106 cpm of [~25I]CSVTCG  binding protein in equil- 
ibration buffer was added with mixing and incubated for 1 h at room 
temperature.  The resins were gently centrifuged to remove excess 
liquid,  and washed twice with 200/~1 of equilibration  buffer fol- 
lowed by two more washes of  equilibration buffer containing 0.5 M 
NaC1. Resins were then eluted with 200/zl of 0.1 M citrate buffer, 
pH 3.0, containing 0.05 % NP-40 detergent. The amount of eluted 
radioactivity is depicted in the bar graph. Each value is the average 
of four separate resins and the error bars represent  the standard 
deviation. 
and eluted from TSP and CSVTCG-coupled resins (Fig. 5). 
In the second experiment, CSVTCG derivatized with p25I]- 
BoRon-Hunter reagent was added  to  monolayers of A549 
cells in the presence and absence of anti-CSVTCG antibody 
and  cross-linked with a  water soluble cross-linking agent 
(Fig. 6). In the absence of antibody, CSVTCG became cell- 
associated in a dose-dependent manner, whereas in the pres- 
ence of antibody cell-association was nearly completely in- 
hibited (top inset, Fig.  6).  Cross-linking of the derivatized 
CSVTCG to cells identified one major band that comigrated 
with  the  purified  CSVTCG  binding  protein  on  SDS-gels 
(bottom inset, Fig. 6).  These experiments indicate that the 
CSVTCG binding protein recognizes CSVTCG both in vitro 
and on the cell surface. 
Characterization of CSVTCG Binding Protein 
To characterize the CSVTCG binding protein, the protein 
was labeled with [~251]iodine and evaluated for its capacity 
to bind TSP.  Analysis of the labeled material by SDS-gel 
electrophoresis followed by autoradiography revealed that 
the  Mr  =  60,000  polypeptide was  predominantly  labeled 
(Fig. 3). The labeled CSVTCG binding protein bound TSP 
in  a  time-dependent manner which became time-indepen- 
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were treated with [125I]CSVTCG  and the amount of cell-associated 
peptide was measured as described in Materials and Methods. The 
top inset shows the amount of cell-associated  peptide when cells 
were incubated with 10 #g/ml of labeled peptide in the presence of 
either  100 #g/ml rabbit IgG or  100 #g/ml rabbit  anti-CSVTCG 
binding protein (anti-CBP). The bottom inset shows an autoradio- 
gram of an SDS-gel of purified CSVTCG binding protein and total 
cell  extract  cross-linked  with BS  3 as described  in Materials  and 
Methods. Proteins were separated on an 8 % gel under nonreducing 
conditions.  Lane 1, purified [125I]CSVTCG  binding protein.  Lane 
2,  total  cell  extract  from cells  cross-linked  in  the  presence  of 
[125I]CSVTCG. 
dent after 60 min (data not shown). The binding was maxi- 
mal in the presence of 1 mM CaC12 and  1 mM MgCl2 or 
1 mM  CaCl2 alone,  whereas  1  mM  MgCl2  and  1  mM 
MnC12 supported significantly less binding  (Fig.  7).  Bind- 
ing (55 % of maximal) was also observed in the presence of 
1 mM EDTA (Fig. 7). The CSVTCG binding protein had the 
greatest binding affinity for TSP whereas fibronectin, BSA, 
and the peptides GRGES and GRGDS had negligible binding 
activity (Fig. 8).  The CSVTCG binding protein bound TSP 
saturably with an apparent binding constant of 0.30 #M. The 
binding constant was estimated from the least squares fit of 
the data to a rectangular hyperbola (correlation coefficient 
of 0.994) assuming Mr -- 50,000 (Fig. 9). This binding was 
reversible because  increasing  concentrations  of unlabeled 
protein  added  to  the  incubation  mixture  caused  a  dose- 
dependent  inhibition  of  binding  (Fig.  9).  Incubation  of 
CSVTCG binding protein with TSP and heparin in the fluid 
phase resulted in a 64 and 80 % inhibition of binding respec- 
tively,  whereas  BSA  and  lactose had  no  effect (Fig.  10). 
These results indicate that the CSVTCG-binding protein can 
interact specifically with TSP in vitro and that binding may 
be  mediated  by  CSVTCG-binding  associated  glycocon- 
jugates.  Consistent with this conclusion is the observation 
that  the  CSVTCG-binding  protein  contains  carbohydrate. 
We found that the purified protein bound galactose-, man- 
nose-, and galactosamine-specific lectins (Table I). 
Figure  7.  The  divalent  ion  requirements  for the  interaction  of 
CSVTCG binding protein with TSE CSVTCG binding protein was 
radiolabeled  with  [~25I]iodine and  binding  to  immobilized  TSP 
was performed as described in Materials and Methods. Concentra- 
tions of all salts and EDTA were 1 mM. The designations Ca, Mn, 
Mg are CaC12, MnC12, and MgC12, respectively. 
The Effect of  Anti-CSVTCG Binding Protein and Anti- 
CSVTCG Peptide Antibody on Tumor CeU Adhesion 
To investigate the importance of the CSVTCG-binding pro- 
tein in mechanisms of TSP-promoted cell substratum adhe- 
sion, a polyclonal CSVTCG binding protein antiserum was 
raised in a rabbit and a polyclonal CSVTCG antiserum was 
Figure 8.  The specificity of the interaction  of CSVTCG binding 
protein with TSE CSVTCG binding protein was radiolabeled with 
[~2~I]iodine and binding to the various immobilized proteins  and 
peptides was performed as described  in Materials  and Methods. 
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Figure  9. Concentration dependence of the binding of 125I-labeled 
CSVTCG binding protein to aSP. Binding was performed to im- 
mobilized aSP in binding buffer containing 1 mM CaCI2  and 1 mM 
MgCt2 as described in Materials and Methods. The closed squares 
show specific binding to aSP and the open squares show binding 
to BSA. Specific binding is defined as cpm bound to aSP minus 
cpm bound to BSA. Values  given are the mean  of two duplicate de- 
terminations and are representative  of a typical experiment. Dupli- 
cate values  differed by no more than 5  %. The line drawn was com- 
puter generated by a least squares fit to a rectangular hyperbola 
with a calculated dissociation constant of 0.30 #M (GraphPad In- 
plot, Version 3.1, San Diego, CA). The inset shows binding per- 
formed  as  above except that  the  ratio  of unlabeled to  labeled 
CSVTCG binding protein was progressively increased. 
raised in a goat. The antibodies were monospecific as deter- 
mined by direct ELISA (data not shown) and by immunoblot 
analysis (Fig.  11). Anti-CSVTCG binding protein antibody 
specifically recognized the Mr =  60,000 subunit of purified 
CSVTCG  binding  protein  and  A549  cell  extracts  under 
reducing conditions (Fig.  11 A). Anti-CSVTCG recognized 
the 180-kD subunit of TSP and a minor 160-kD degradation 
product (Fig.  11 B). Both anti-CSVTCG and anti-CSVTCG 
binding protein IgG fractions almost completely inhibited 
A549 cell adhesion to TSP-coated surfaces but had no effect 
on cell adhesion to fibronectin or laminin (Fig. 12). In addi- 
tion, both anti-CSVTCG and anti-CSVTCG binding protein 
IgG nearly totally prevented cell spreading on TSP but had 
no effect on FN and laminin-mediated cell spreading (data 
not shown).  These results  strongly suggest that the  CSV- 
TCG-binding protein functions as a TSP cell adhesion recep- 
tor and the TSP sequence, CSVTCG, functions as a tumor 
cell adhesive domain of TSE Consistent with this interpreta- 
tion is the cell surface orientation of the CSVTCG-binding 
protein which could be labeled with [125I]iodine on intact 
cells (Fig.  3). 
Figure 10. The effect of fluid-phase aSP, IgG, lactose, heparin, and 
anti-CSVTCG  binding protein (anfi-CBP)  on the binding of  CSVTCG 
binding protein to immobilized aSP.  Binding was .performed in 
binding buffer containing either 10 #g/ml BSA, 10 #g/ml aSP, 100 
/~g/ml lactose,  100/~g/ml heparin,  100 #g/ml rabbit. IgG, or 100 
#g/ml anti-CBP. The 100% control for lactose, heparin and aSP 
was the amount bound in the presence of fluid phase BSA. The 
100% control for anti-CBP was the amount bound in the presence 
of rabbit IgG. Values given were calculated from the mean of two 
duplicate determinations and are representative of a typical experi- 
ment. Duplicate values differed by no more than 5 %. 
Discussion 
A major focus of our work has been to show that TSP plays 
a significant role in the pathogenesis of tumor spread.  Sev- 
eral lines of evidence both from our laboratory and from the 
work of others strongly suggest that TSP may mediate one 
or more steps in the metastatic cascade. We observed that 
mice injected with tumor cells together with TSP developed 
2-3 times more lung metastases than did controls (27). A 
likely explanation for these results is that TSP promoted the 
Table L  Lectin-CSVTCG Binding Protein Interactions 
Lectin  Bound cpm  Sugar specificity 
Concanavalin  A  1263  alpha-D-man 
glucose 
Lens culinaris  896  alpha-D-man 
Lycopersicon  2140  (D-glcNAc)3 
esculentum 
Ptilota plumosa 
Dolichos biflorus 
Tetragonolobus 
purpureas 
1112  alpha-D-gal 
379  alpha-D-galNAc 
641  alpha-L-rue 
Lectins were coated in microtiter wells by incubating each well with 100 #1 of 
a 40 #g/ml solution of lectin in PBS. Wells were washed twice in PBS, blocked 
with BSA, and incubated with 50/zl of [125I]CSVTCG binding protein in bind- 
ing buffer (130,000 clam). Wells were washed twice in PBS and bound radioac- 
tivity counted.  The amount bound to BSA-coated plates which accounted for 
<9% of the observed radioactivity was subtracted from each value given in the 
table. Values are the average of three determinations which varied by <5 %. 
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anti-CSVTCG by immunoblotting.  Proteins were analyzed on an 
8-25%  gradient  gel  under  reducing  conditions  as  described  in 
Materials and Methods. (A) Anti-CSVTCG binding protein blot of 
purified CSVTCG binding protein (lane/), SDS extract of A549 
whole cells (lane 2), IgG blot of CSVTCG binding protein (lane 3), 
IgG blot of A549 cells (lane 4). (B) Anti-CSVTCG blot of purified 
TSP (lane/), IgG blot of TSP (lane 2). 
Figure 12. The effect of  anti-CSVTCG binding protein antibody and 
anti-CSVTCG peptide antibody on TSP-dependent A549 tumor cell 
adhesion. A549 tumor cells (1 ml of a 4  x  105/ml cell suspension 
in DME) were treated with either 200 #g/ml control rabbit IgG or 
200 #g/ml anti-CSVTCG binding protein IgG for 30 min at 37~ 
Excess  antibody  was  removed by centrifugation  and  cells  were 
resuspended in DME. Ceils were then added to protein-coated mi- 
crotiter dishes and the number of adherent cells determined  after 
1 h as previously described (31, 34). In the case of anti-CSVTCG 
antibody, TSP-coated  dishes were incubated with either 100/~1 of 100 
#g/ml solution of anti-CSVTCG antibody or control goat IgG for 
30 min at 37~  before addition of cells. The number of adherent 
cells were measured after 1 h.  Approximately 200-400 cells ad- 
hered  per  1 mm  2 of tissue culture plate coated  with either  TSP, 
fibronectin (FN) or laminin (LM) in the presence  of control IgG 
(designated as control).  All values were the average of duplicates 
which varied by <5 %. 
adhesion of tumor cells to the vessel wall because there were 
initially more tumor cells trapped in the lungs of the TSP- 
treated animals than in controls. In addition, the metastatic 
colonies in the TSP-treated animals were significantly larger 
than in the non-TSP treated animals suggesting that TSP may 
have had an effect on the growth and aggregate size of the 
cells.  To determine whether high levels of circulating TSP 
could be playing a role in the pathogenesis of human cancer, 
plasma TSP levels of various cancer patients were measured. 
We found that patients with breast cancer, lung cancer, and 
colon cancer had circulating plasma TSP-levels two to three- 
fold higher than normal controls or patients with noncancer 
illnesses (35).  Similar results were found for patients with 
myeloproliferative disorders  (17),  and  gynecologic malig- 
nancies (18).  TSP could not only promote the adhesion of 
these human tumors and thereby promote metastasis forma- 
tion but also enhance the metastatic potential of these cells. 
The latter conclusion was supported by the study of Castle 
et al. (7) who showed that production of TSP by human squa- 
mous carcinoma tumors correlated with the expression of the 
malignant phenotype because the antisense reduction of TSP 
message resulted  in  tumors that were nonmetastatic, slow 
growing,  and highly differentiated.  Therefore, tumor cells 
may utilize both endogenously expressed TSP and platelet- 
released TSP as anchors for attachment to the vascular base- 
ment membrane and  as  promoters of the  malignant phe- 
notype. 
It is clear from a number of studies that TSP can bind to 
multiple cell surface receptors on the same cell or bind to 
different receptors on different cells. For example, platelets 
can bind TSP through  GPIIb-IIIa (10, 30),  the  vitronectin- 
receptor (14),  and GPIa-IIa (30).  Smooth muscle ceils (16), 
endothelial cells (16),  U937  monocyte-like cells (16),  and 
melanoma cells can bind TSP (28) through a vitronectin-like 
receptor.  Squamous cell carcinoma cells bind TSP through 
an Mr  =  80,000/105,000  protein that is not an integrin or 
GPIV (40). 
The  involvement  in  TSP  cell  adhesive  interactions  of 
GPIV or CD36, originally described as a monocyte specific 
antigen  (12),  remains  controversial.  Originally,  Asch  and 
colleagues (4) demonstrated that TSP binding to activated 
platelets, melanoma cells, and fibrosarcoma cells could be 
inhibited by a monoclonal antibody to GPIV, OKM5 (12). 
These cells contained GPIV on their surfaces and isolated 
GPIV could be shown to bind TSP in vitro. However, Aiken 
et al. (1) could not block platelet surface TSP expression with 
anti-GPIV antibody  and  the  analysis  was  further  compli- 
cated by the fact that anti-GPIV caused platelet activation. 
Platelets deficient in GPIV bound TSP to the same extent as 
normal platelets suggesting that other platelet receptors were 
capable of binding  TSP  (11). Anti-GPIV alone could  not 
block TSP-mediated cell adhesion but did so weakly in the 
presence of high levels of heparin suggesting that GPIV is 
not a primary mediator of adhesion in this system despite the 
fact  that  previous  in  vitro  assays  performed  by  different 
groups show that isolated GPIV could bind TSP (2, 6). Initial 
studies showing that GPIV mediated TSP-monocyte binding 
(24, 25) have recently been called into question because the 
same results could be obtained by measuring the binding of 
TSP  to  a  calcium  precipitate  formed by  the  addition  of 
CaC12 to  the  binding  medium  used  in  the  initial  studies 
(26). Finally, two opposite results were obtained from GPIV 
transfection studies. Oquendo et al. (19) found that COS cells 
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compared to controls. In contrast, Asch et al. (5) found that 
Jurkat  cells  transfected with  GPIV  bound  TSP  saturably 
whereas control cells showed little or no binding. One differ- 
ence in these transfection studies is the cell type used. COS 
cells are adherent cells and Jurkat cells are suspension cells. 
It would be interesting to know if the GPIV-transfected Jur- 
kat cells became adherent especially on TSP-coated surfaces. 
As described above, TSP plays a  major role in cellular 
adhesion. We recently identified a TSP cell adhesion domain 
that consisted of the hexapeptide sequence, CSVTCG (32). 
Synthetic  CSVTCG  peptides  and  homologous  analogues 
promoted the adhesion of A549 lung carcinoma, B16-F10 
melanoma cells, bovine aortic endothelial cells, and rabbit 
smooth muscle cells. These peptides inhibited platelet aggre- 
gation  and  the  complex process of tumor cell metastasis 
which depends in part on TSP adhesive activity (27).  We 
postulated  that  the  way  these  peptides  inhibited  platelet 
aggregation and tumor cell metastasis was to bind to cell sur- 
face receptors specific for CSVTCG and TSP and thereby 
compete for endogenous TSP adhesive interactions. 
To test this hypothesis, CSVTCG A549 tumor cell binding 
proteins were isolated and characterized in an in vitro TSP 
binding and cell adhesion assay.  Chromatography of A549 
cell detergent extracts on a CSVTCG peptide affinity column 
yielded one tightly-bound protein peak that was  eluted at 
high pH. The protein appeared homogenous because it could 
be eluted as a single peak from an anion exchange column 
and analyzed by isoelectric focusing as a homogeneous band 
having a pI of 4.7. The protein appeared to be glycosylated 
because it bound to galactose, glucosamine, and mannose 
specific lectins.  Consistent with the presence of glycocon- 
jugate was the high 260 nm absorbance of the purified pro- 
tein and the capacity of heparin to inhibit the binding interac- 
tion between TSP. On SDS gels under reducing conditions, 
the protein migrated as two major polypeptide bands spaced 
closely together with apparent molecular weights of 60,000 
and 50,000 kD. Under nonreducing conditions, a single band 
of 50,000 kD was observed but in some preparations small 
amounts  of  dimers  could  be  observed  with  molecular 
weights >100,000 kD.  These results are consistent with the 
interpretation  that  the  protein  consists  of two  interchain 
disulfide-linked polypeptide chains that assume a more com- 
pact configuration when disulfide bonded. 
The CSVTCG binding protein is surface exposed in A549 
cells because it could be labeled with [~25I]iodine on intact 
cells. In addition, a rabbit polyclonal antibody raised against 
the protein inhibited adhesion and spreading of A549 cells 
to TSP but not to fibronectin or laminin indicating that not 
only is the CSVTCG binding protein surface exposed but it 
is also functioning as a TSP adhesion receptor. Blockage of 
the ligand for the CSVTCG binding protein on TSP with anti- 
CSVTCG peptide antibody also inhibited TSP-promoted cell 
adhesion and spreading. These results suggest that cells uti- 
lize the CSVTCG-binding protein to adhere and spread on 
TSP-coated tissue culture plates. 
To determine whether the CSVTCG could function as a 
receptor for TSP in vitro, labeled CSVTCG binding protein 
was  evaluated for its capacity to bind TSP. We found that 
CSVTCG binding protein interacted with TSP saturably and 
in an ion-dependent manner.  The calculated binding con- 
stant was 0.3 #M or 2.3 times more favorable than the bind- 
ing  interaction of TSP with  GPIa-IIa,  a  high  affinity TSP 
binding protein in platelets (41). The binding interaction did 
not involve RGD sequences because no significant binding 
was  observed on GRGDS or fibronectin.  The observation 
that heparin inhibited the interaction between the CSVTCG 
binding  protein and  TSP suggests  that  sulfated glycocon- 
jugates may be involved in the binding interaction. It is possi- 
ble that CSVTCG and adjacent downstream sequences con- 
taining  arginine  could  provide  secondary  conformation 
dependent heparin binding domains in TSP. In support of  this 
conclusion is the observation that CSVTCR binds heparin 
(unpublished data). Therefore under in vitro conditions, the 
CSVTCG-binding protein could function as a binding pro- 
tein for TSP and the binding interaction could be mediated 
by  sulfated  glycoconjugates  associated  with  the  purified 
CSVTCG binding protein. 
To determine whether the CSVTCG binding protein func- 
tions to bind CSVTCG containing proteins in vivo, CSV- 
TCG cell association studies were performed. We found that 
A549 cells bound CSVTCG in a dose-dependent manner. 
The binding was inhibited by anti-CSVTCG binding protein 
antibody and CSVTCG was  cross-linked to cell-associated 
CSVTCG binding protein. These experiments further sug- 
gest that CSVTCG binding protein functions as a cell surface 
receptor for proteins containing the CSVTCG sequence. 
Further analysis of the CSVTCG binding protein is cur- 
rently underway. The protein does not cross-react with anti- 
bodies against integrins, GPIV, or the laminin receptor (data 
not shown). Attempts at partial sequence analysis have been 
unsuccessful due to blocked end groups.  This protein may 
represent a new class of adhesion molecules that could func- 
tion in the TSP-adhesive interactions operative during cell- 
matrix interactions and during the pathogenesis of tumor cell 
metastasis. 
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